ClinicalTrials.gg

Program

dalpiciclib isethionate

Also written as “HRS-8080 Tablet ; Dalpiciclib Isethionate”, “HRS-8080; Dalpiciclib Isethionate Tablets” and “dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets”.

Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jan 8, 20264 company-led studies, 4 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine44 open or runningphase 3since Jan 8, 2026Feb 17, 2023Dec 2028phase 3 · NCT07354022

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2023First study: phase 2 study in Breast NeoplasmsFirst studyNCT05792410 · 300 planned
  2. Oct 13, 2023Phase 1 study in Neoplasm MetastasisNCT06099990 · 660 planned
  3. Dec 4, 2023Phase 2 study in Breast NeoplasmsNCT06167694 · 146 planned · China
  4. Jan 8, 2026Phase 3 study in Breast NeoplasmsPhase 3 reachedNCT07354022 · 912 planned · China

Ahead

  1. Dec 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07354022
  2. Dec 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT06099990

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07354022Breast Neoplasms · China3RecruitingDec 2028912
NCT06167694Breast Neoplasms · China2RecruitingJun 2026146
NCT06099990Neoplasm Metastasis1Not yet recruitingDec 2028660
NCT05792410Breast Neoplasms2Not yet recruitingFeb 27, 2024300

How it is read

Names in the registry

  • “HRS-8080 Tablet ; Dalpiciclib Isethionate”, 1 entry
  • “HRS-8080; Dalpiciclib Isethionate Tablets”, 1 entry
  • “dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets”, 1 entry
  • “SHR-A1811 & Dalpiciclib Isethionate Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.